In a statement on Friday, the two companies said their submission to the European Medicines Agency was based on an advanced study in more than 2,000 adolescents that showed the vaccine to be safe and effective. The children will continue to be monitored for longer-term protection and safety for another two years.
BioNTech and Pfizer previously had requested their emergency use authorisation with the U.S. Food and Drug Administration also be extended to children 12-15.
The COVID-19 vaccine made by Pfizer and BioNTech was the first one to be granted a greenlight by the EMA in December, when it was licensed for anyone age 16 and over across the 27-nation EU.
Image Source : PTI/FILE IMAGE Mamata arrives in Delhi on 5-day visit, to meet PM Modi, opp…